MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

Phase 2
Completed
Conditions
Endometrial Cancer
Cervical Cancer
Uterine Cancer
Interventions
First Posted Date
2017-06-19
Last Posted Date
2021-09-08
Lead Sponsor
University Hospital, Ghent
Target Recruit Count
43
Registration Number
NCT03192059
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

🇧🇪

University Hospital Antwerp, Antwerp, Belgium

🇧🇪

University Hospital Gent, Gent, Belgium

and more 1 locations

CES1 Carriers in the PAPI Study

Phase 4
Completed
Conditions
Heart Diseases
Coronary Disease
Coronary Artery Disease
Cardiovascular Diseases
Myocardial Ischemia
Artery Occlusion
Aspirin Sensitivity
Clopidogrel, Poor Metabolism of
Platelet Dysfunction
Platelet Thrombus
Interventions
First Posted Date
2017-06-15
Last Posted Date
2023-06-15
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
6
Registration Number
NCT03188705
Locations
🇺🇸

Amish Research Clinic, Lancaster, Pennsylvania, United States

Preventive Application of GnRH Antagonist on Early OHSS

Phase 4
Conditions
GnRH Antagonist
Pigment Epithelium Derived Factor
Ovarian Hyperstimulation Syndrome
Vascular Endothelial Growth Factor
Aspirin
Interventions
First Posted Date
2017-06-15
Last Posted Date
2017-06-15
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
175
Registration Number
NCT03188471
Locations
🇨🇳

The First Affiliated Hospital of Sun Yatsen University, Guangzhou, Guangdong, China

Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

Phase 2
Terminated
Conditions
Locally Advanced Malignant Neoplasm
Chemoradiation
Rectal Cancer, Adenocarcinoma
Interventions
Drug: Placebo Oral Tablet
Drug: Aspirin
First Posted Date
2017-05-30
Last Posted Date
2020-12-17
Lead Sponsor
Instituto Nacional de Cancer, Brazil
Target Recruit Count
25
Registration Number
NCT03170115
Locations
🇧🇷

INCA- Instituto Nacional de Câncer, Rio de Janeiro, Brazil

A Project to Improve the Diagnosis and Prognosis of Myocardial Injury Associated to Non Cardiac Surgery

Completed
Conditions
Myocardium; Injury
Interventions
Diagnostic Test: Troponin
Drug: Acetylsalicylic acid
Drug: Statin
First Posted Date
2017-04-28
Last Posted Date
2022-03-22
Lead Sponsor
Parc de Salut Mar
Target Recruit Count
800
Registration Number
NCT03133260
Locations
🇪🇸

Hospital Del Mar, Barcelona, Spain

Analgesic Effects of Transversus Thoracic Plane (TTP) Block in Cardiac Surgery

Not Applicable
Conditions
Nerve Block
Postoperative Pain
Cardiac Surgery
Interventions
First Posted Date
2017-04-25
Last Posted Date
2017-09-05
Lead Sponsor
Western University, Canada
Target Recruit Count
100
Registration Number
NCT03128346
Locations
🇨🇦

London Health Sciences Centre, London, Ontario, Canada

Chronic Subdural Hematoma and Aspirin

Not Applicable
Completed
Conditions
Chronic Subdural Hematoma
Interventions
Drug: Placebo Oral Tablet
Drug: Acetylsalicylic acid
First Posted Date
2017-04-19
Last Posted Date
2024-05-13
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
150
Registration Number
NCT03120182
Locations
🇨🇭

Department of Neurosurgery, Basel, Switzerland

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Phase 4
Terminated
Conditions
Coronary Artery Disease
Atherosclerosis
Stents
Interventions
First Posted Date
2017-04-18
Last Posted Date
2024-04-22
Lead Sponsor
Samsung Medical Center
Target Recruit Count
25
Registration Number
NCT03119012
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients

Phase 4
Completed
Conditions
Ischemic Stroke
Endothelial Dysfunction
Interventions
First Posted Date
2017-04-17
Last Posted Date
2017-04-17
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
80
Registration Number
NCT03116269
Locations
🇰🇷

Ajou University Medical Center, Suwon, Gyunggido, Korea, Republic of

Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

Phase 4
Conditions
Coronary Artery Disease
Acute Coronary Syndrome
Interventions
Drug: Aspirin
Drug: P2Y12 inhibitor
First Posted Date
2017-04-13
Last Posted Date
2019-08-07
Lead Sponsor
Humanitas Hospital, Italy
Target Recruit Count
1023
Registration Number
NCT03112707
Locations
🇮🇹

Humanitas Research Hospital, Rozzano, Milan, Italy

© Copyright 2025. All Rights Reserved by MedPath